Marion de Jong

List of Publications by Year
in descending order

86 papers	3,047 citations	159585 30 h-index	182427 51 g-index
90 all docs	90 docs citations	90 times ranked	3770 citing authors

#	Article	IF	Citations
1	Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and InÂVivo Survival. Journal of Nuclear Medicine, 2022, 63, 100-107.	5.0	8
2	The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In Vivo. Pharmaceutics, 2022, 14, 173.	4.5	3
3	Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer. Pharmaceutics, 2022, 14, 195.	4.5	6
4	Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain. Cancers, 2022, 14, 861.	3.7	0
5	In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	6.4	12
6	Imaging inflammation in atherosclerotic plaques, targeting SST2 with [111In]In-DOTA-JR11. Journal of Nuclear Cardiology, 2021, 28, 2506-2513.	2.1	12
7	Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1339-1350.	6.4	42
8	Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. Theranostics, 2021, 11, 491-505.	10.0	23
9	To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the â€œHoly Grayâ€•in radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2680-2682.	6.4	9
10	Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma. Journal of Neuro-Oncology, 2021, 153, 211-222.	2.9	7
11	Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification. EJNMMI Research, 2021, 11, 27.	2.5	7
12	Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy. Cancers, 2021, 13, 1100.	3.7	35
13	GRPr Antagonist ⁶⁸Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-NaÃ¯ve Patients. Journal of Nuclear Medicine, 2021, 62, 1517-1523.	5.0	17
14	Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: a consequence from cyanine-labeling of small molecules. EJNMMI Research, 2021, 11, 47.	2.5	5
15	Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nuclear Medicine and Biology, 2021, 102-103, 1-11.	0.6	31
16	Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications. Current Radiopharmaceuticals, 2021, 14, 184-208.	0.8	2
17	Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [111In]In-DOTATATE Uptake in NET Cells. Cancers, 2021, 13, 4905.	3.7	11
18	Modeling early radiation DNA damage occurring during [¹⁷⁷Lu]Lu-DOTA-[Tyr³]octreotate radionuclide therapy. Journal of Nuclear Medicine, 2021, , jnumed.121.262610.	5.0	2

#	Article	IF	Citations
19	In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid Tumors. Contrast Media and Molecular Imaging, 2021, 2021, 1-8.	0.8	3
20	Imaging DNA Damage Repair In Vivo After ¹⁷⁷Lu-DOTATATE Therapy. Journal of Nuclear Medicine, 2020, 61, 743-750.	5.0	33
21	In Vivo Evaluation of Indium-111â€"Labeled 800CW as a Necrosis-Avid Contrast Agent. Molecular Imaging and Biology, 2020, 22, 1333-1341.	2.6	6
22	Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2856-2865.	6.4	5
23	Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward. Current Topics in Medicinal Chemistry, 2020, 20, 2959-2969.	2.1	27
24	Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity. EJNMMI Physics, 2020, 7, 8.	2.7	23
25	The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research. Pharmaceutics, 2019, 11, 560.	4.5	51
26	Call to arms: need for radiobiology in molecular radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1588-1590.	6.4	23
27	Perspectives on Small Animal Radionuclide Imaging; Considerations and Advances in Atherosclerosis. Frontiers in Medicine, 2019, 6, 39.	2.6	14
28	Trastuzumab cotreatment improves survival of mice with PCâ€3 prostate cancer xenografts treated with the GRPR antagonist ¹⁷⁷Luâ€DOTAGAâ€PEG₂â€RM26. International Journal of Cancer, 2019, 145, 3347-3358.	5.1	30
29	Comparative evaluation of the new GRPRâ€antagonist ¹¹¹Inâ€SB9 and ¹¹¹Inâ€AMBA in prostate cancer models: Implications of in vivo stability. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 646-655.	1.0	10
30	Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin. Bioconjugate Chemistry, 2018, 29, 1774-1784.	3.6	27
31	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acidâ€"Mediated Pretargeting: In Vivo Proof of Principle. Journal of Nuclear Medicine, 2018, 59, 1092-1098.	5.0	48
32	In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer. Molecular Imaging and Biology, 2018, 20, 973-983.	2.6	13
33	Translational molecular imaging in exocrine pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2442-2455.	6.4	17
34	SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?. Journal of Nuclear Medicine, 2017, 58, 1609-1614.	5.0	21
35	Comparing the therapeutic potential of thermosensitive liposomes and hyperthermia in two distinct subtypes of breast cancer. Journal of Controlled Release, 2017, 258, 34-42.	9.9	19
36	Intravenous and intratumoral injection of Pluronic P94: The effect of administration route on biodistribution and tumor retention. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2179-2188.	3.3	8

#	Article	IF	Citations
37	²¹³Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 67-73.	1.0	47
38	The new era of cancer immunotherapy: what can molecular imaging do to help?. Clinical and Translational Imaging, 2017, 5, 299-301.	2.1	8
39	Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results. Journal of Nuclear Medicine, 2017, 58, 75-80.	5.0	129
40	Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 9.	3.9	18
41	⁶⁸Ga/¹⁷⁷Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. Journal of Nuclear Medicine, 2017, 58, 293-299.	5.0	98
42	Review: Receptor Targeted Nuclear Imaging of Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 260.	4.1	27
43	Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 11.	3.9	4
44	Generation of fluorescently labeled tracers â€“ which features influence the translational potential?. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 15.	3.9	15
45	New tracers to the clinic. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 133-134.	0.7	2
46	Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. PLoS ONE, 2017, 12, e0170536.	2.5	8
47	In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. PLoS ONE, 2017, 12, e0181473.	2.5	37
48	Preclinical in vivo cancer, straightway to patients?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 145-152.	0.7	4
49	In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies. Theranostics, 2016, 6, 104-117.	10.0	53
50	Investigation of Particle Accumulation, Chemosensitivity and Thermosensitivity for Effective Solid Tumor Therapy Using Thermosensitive Liposomes and Hyperthermia. Theranostics, 2016, 6, 1717-1731.	10.0	38
51	Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics, 2016, 6, 849-861.	10.0	102
52	Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. Theranostics, 2016, 6, 1821-1832.	10.0	100
53	Breast cancer imaging using radiolabelled somatostatin analogues. Nuclear Medicine and Biology, 2016, 43, 559-565.	0.6	19
54	Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine Xenografts. Journal of Nuclear Medicine, 2016, 57, 1289-1295.	5.0	20

#	ARTICLE	IF	CITATIONS
55	99mTc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice. Nuclear Medicine and Biology, 2016, 43, 347-354.	0.6	15
56	Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate. EJNMMI Research, 2016, 6, 6.	2.5	31
57	Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine. EJNMMI Research, 2016, 6, 83.	2.5	53
58	Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11â€"first estimates for clinical translation. EJNMMI Research, 2016, 6, 15.	2.5	23
59	Radiolabeling polymeric micelles for in vivo evaluation: a novel, fast, and facile method. EJNMMI Research, 2016, 6, 12.	2.5	24
60	Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 964-973.	6.4	90
61	Utilizing High-Energy Î³-Photons for High-Resolution 213Bi SPECT in Mice. Journal of Nuclear Medicine, 2016, 57, 486-492.	5.0	27
62	Improving the <i>In Vivo</i> Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 20-28.	1.0	24
63	Investigation of Factors Determining the Enhanced Permeability and Retention Effect in Subcutaneous Xenografts. Journal of Nuclear Medicine, 2016, 57, 601-607.	5.0	37
64	Comparison of the Therapeutic Response to Treatment with a ¹⁷⁷Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. Journal of Nuclear Medicine, 2016, 57, 260-265.	5.0	102
65	Optimized timeâ€resolved imaging of contrast kinetics (TRICKS) in dynamic contrastâ€enhanced MRI after peptide receptor radionuclide therapy in small animal tumor models. Contrast Media and Molecular Imaging, 2015, 10, 413-420.	0.8	6
66	A Novel ¹¹¹In-Labeled Antiâ€"Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 1094-1099.	5.0	102
67	In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin 111In-radioligands. Nuclear Medicine and Biology, 2015, 42, 824-832.	0.6	15
68	Highlights lecture EANM 2014: â€œGimme gimme gimme those nuclear Super Troupersâ€ European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 781-802.	6.4	0
69	Radiopeptides for Imaging and Therapy: A Radiant Future. Journal of Nuclear Medicine, 2015, 56, 1809-1812.	5.0	50
70	In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer. Journal of Nuclear Medicine, 2015, 56, 752-757.	5.0	49
71	Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 1487-1493.	5.0	30
72	Preclinical Comparison of Al¹⁸F- and ⁶⁸Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2014, 55, 2050-2056.	5.0	46

#	Article	IF	Citations
73	Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clinical and Translational Imaging, 2014, 2, 55-66.	2.1	66
74	Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model. EJNMMI Research, 2014, 4, 21.	2.5	14
75	[DOTA]Somatostatin-14 analogs and their 111In-radioligands: Effects of decreasing ring-size on sst1â€“5 profile, stability and tumor targeting. European Journal of Medicinal Chemistry, 2014, 73, 30-37.	5.5	12
76	Imaging preclinical tumour models: improving translational power. Nature Reviews Cancer, 2014, 14, 481-493.	28.4	153
77	Quantification of DCE-MRI: A validation of three techniques with 3D-histology. , 2012, , .		1
78	PL - 92. Non-invasive determination of the beta cell mass in rats by SPECT with In-111-DTPA-Exendin-3. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 154-155.	0.0	0
79	Of Mice and Humans: Are They the Same?â€"Implications in Cancer Translational Research: TABLE 1. Journal of Nuclear Medicine, 2010, 51, 501-504.	5.0	164
80	Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues. Accounts of Chemical Research, 2009, 42, 873-880.	15.6	168
81	Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 763-771.	6.4	43
82	Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. Journal of Nuclear Medicine, 2005, 46, 1696-700.	5.0	73
83	Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. Journal of Nuclear Medicine, 2004, 45, 1168-71.	5.0	49
84	Radiolabelled peptides for tumour therapy: current status and future directions. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 463-469.	6.4	114
85	Plasma Membrane Transport of Thyroid Hormones and Its Role in Thyroid Hormone Metabolism and Bioavailability. , 2001, 22, 451-476.		92
86	Transport of thyroxine into cultured hepatocytes: effects of mild nonâ€thyroidal illness and calorie restriction in obese subjects. Clinical Endocrinology, 1994, 40, 79-85.	2.4	33